Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses

Angelique St. Antoine, Morgan N. Ketterling, William R. Sukov, Josh Lowman, Ryan A. Knudson, Jason P. Sinnwell, Anne E. Wiktor, Rhett P. Ketterling

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context.-Clotted blood and bone marrow specimens account for a large proportion of failed cytogenetic studies. There are no published protocols describing salvage of clotted specimens such that conventional chromosome or fluorescence in situ hybridization (FISH) studies can be performed. Objective.-To evaluate the utility of thrombolytic drugs on clotted blood samples to yield intact cells suitable for cytogenetic analysis. Design.-Five commercially available thrombolytic drugs (alteplase, urokinase, streptokinase, tenecteplase, reteplase) were evaluated in a series of blinded experiments to identify the best drug for lysing clots to produce samples suitable for chromosome and FISH studies. After the selection of alteplase as the drug yielding the most promising results, a comparative study between alteplase (0.75 mg/ml) and a commercially available anticlotting reagent (ACR) was performed. For each sample, mitotic index, chromosome length, and quality of slides prepared for conventional chromosome and FISH analyses were evaluated. Results.-Alteplase-treated samples produced a higher mitotic index than those treated with ACR while showing equivalent quality in conventional chromosome and FISH studies. We have demonstrated the utility of treating clotted blood samples with alteplase before cell culture to yield cells suitable for cytogenetic analysis. Since clinical implementation, this technique has been applied to more than 250 bone marrow samples, with a 93% success rate. Conclusions.-We believe the routine use of alteplase on clotted blood and bone marrow specimens should become standard for cytogenetics laboratories and may have similar utility in salvaging clotted specimens for other clinical assays requiring intact cells for analysis.

Original languageEnglish (US)
Pages (from-to)915-919
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume135
Issue number7
StatePublished - Jul 2011

Fingerprint

Fibrinolytic Agents
Cytogenetic Analysis
Tissue Plasminogen Activator
Bone Marrow
Fluorescence In Situ Hybridization
Chromosomes
Mitotic Index
Cytogenetics
Streptokinase
Urokinase-Type Plasminogen Activator
Pharmaceutical Preparations
Cell Culture Techniques

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

St. Antoine, A., Ketterling, M. N., Sukov, W. R., Lowman, J., Knudson, R. A., Sinnwell, J. P., ... Ketterling, R. P. (2011). Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. Archives of Pathology and Laboratory Medicine, 135(7), 915-919.

Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. / St. Antoine, Angelique; Ketterling, Morgan N.; Sukov, William R.; Lowman, Josh; Knudson, Ryan A.; Sinnwell, Jason P.; Wiktor, Anne E.; Ketterling, Rhett P.

In: Archives of Pathology and Laboratory Medicine, Vol. 135, No. 7, 07.2011, p. 915-919.

Research output: Contribution to journalArticle

St. Antoine, A, Ketterling, MN, Sukov, WR, Lowman, J, Knudson, RA, Sinnwell, JP, Wiktor, AE & Ketterling, RP 2011, 'Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses', Archives of Pathology and Laboratory Medicine, vol. 135, no. 7, pp. 915-919.
St. Antoine, Angelique ; Ketterling, Morgan N. ; Sukov, William R. ; Lowman, Josh ; Knudson, Ryan A. ; Sinnwell, Jason P. ; Wiktor, Anne E. ; Ketterling, Rhett P. / Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. In: Archives of Pathology and Laboratory Medicine. 2011 ; Vol. 135, No. 7. pp. 915-919.
@article{ff4d486112404077b502dee4f361a5ed,
title = "Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses",
abstract = "Context.-Clotted blood and bone marrow specimens account for a large proportion of failed cytogenetic studies. There are no published protocols describing salvage of clotted specimens such that conventional chromosome or fluorescence in situ hybridization (FISH) studies can be performed. Objective.-To evaluate the utility of thrombolytic drugs on clotted blood samples to yield intact cells suitable for cytogenetic analysis. Design.-Five commercially available thrombolytic drugs (alteplase, urokinase, streptokinase, tenecteplase, reteplase) were evaluated in a series of blinded experiments to identify the best drug for lysing clots to produce samples suitable for chromosome and FISH studies. After the selection of alteplase as the drug yielding the most promising results, a comparative study between alteplase (0.75 mg/ml) and a commercially available anticlotting reagent (ACR) was performed. For each sample, mitotic index, chromosome length, and quality of slides prepared for conventional chromosome and FISH analyses were evaluated. Results.-Alteplase-treated samples produced a higher mitotic index than those treated with ACR while showing equivalent quality in conventional chromosome and FISH studies. We have demonstrated the utility of treating clotted blood samples with alteplase before cell culture to yield cells suitable for cytogenetic analysis. Since clinical implementation, this technique has been applied to more than 250 bone marrow samples, with a 93{\%} success rate. Conclusions.-We believe the routine use of alteplase on clotted blood and bone marrow specimens should become standard for cytogenetics laboratories and may have similar utility in salvaging clotted specimens for other clinical assays requiring intact cells for analysis.",
author = "{St. Antoine}, Angelique and Ketterling, {Morgan N.} and Sukov, {William R.} and Josh Lowman and Knudson, {Ryan A.} and Sinnwell, {Jason P.} and Wiktor, {Anne E.} and Ketterling, {Rhett P.}",
year = "2011",
month = "7",
language = "English (US)",
volume = "135",
pages = "915--919",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "7",

}

TY - JOUR

T1 - Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses

AU - St. Antoine, Angelique

AU - Ketterling, Morgan N.

AU - Sukov, William R.

AU - Lowman, Josh

AU - Knudson, Ryan A.

AU - Sinnwell, Jason P.

AU - Wiktor, Anne E.

AU - Ketterling, Rhett P.

PY - 2011/7

Y1 - 2011/7

N2 - Context.-Clotted blood and bone marrow specimens account for a large proportion of failed cytogenetic studies. There are no published protocols describing salvage of clotted specimens such that conventional chromosome or fluorescence in situ hybridization (FISH) studies can be performed. Objective.-To evaluate the utility of thrombolytic drugs on clotted blood samples to yield intact cells suitable for cytogenetic analysis. Design.-Five commercially available thrombolytic drugs (alteplase, urokinase, streptokinase, tenecteplase, reteplase) were evaluated in a series of blinded experiments to identify the best drug for lysing clots to produce samples suitable for chromosome and FISH studies. After the selection of alteplase as the drug yielding the most promising results, a comparative study between alteplase (0.75 mg/ml) and a commercially available anticlotting reagent (ACR) was performed. For each sample, mitotic index, chromosome length, and quality of slides prepared for conventional chromosome and FISH analyses were evaluated. Results.-Alteplase-treated samples produced a higher mitotic index than those treated with ACR while showing equivalent quality in conventional chromosome and FISH studies. We have demonstrated the utility of treating clotted blood samples with alteplase before cell culture to yield cells suitable for cytogenetic analysis. Since clinical implementation, this technique has been applied to more than 250 bone marrow samples, with a 93% success rate. Conclusions.-We believe the routine use of alteplase on clotted blood and bone marrow specimens should become standard for cytogenetics laboratories and may have similar utility in salvaging clotted specimens for other clinical assays requiring intact cells for analysis.

AB - Context.-Clotted blood and bone marrow specimens account for a large proportion of failed cytogenetic studies. There are no published protocols describing salvage of clotted specimens such that conventional chromosome or fluorescence in situ hybridization (FISH) studies can be performed. Objective.-To evaluate the utility of thrombolytic drugs on clotted blood samples to yield intact cells suitable for cytogenetic analysis. Design.-Five commercially available thrombolytic drugs (alteplase, urokinase, streptokinase, tenecteplase, reteplase) were evaluated in a series of blinded experiments to identify the best drug for lysing clots to produce samples suitable for chromosome and FISH studies. After the selection of alteplase as the drug yielding the most promising results, a comparative study between alteplase (0.75 mg/ml) and a commercially available anticlotting reagent (ACR) was performed. For each sample, mitotic index, chromosome length, and quality of slides prepared for conventional chromosome and FISH analyses were evaluated. Results.-Alteplase-treated samples produced a higher mitotic index than those treated with ACR while showing equivalent quality in conventional chromosome and FISH studies. We have demonstrated the utility of treating clotted blood samples with alteplase before cell culture to yield cells suitable for cytogenetic analysis. Since clinical implementation, this technique has been applied to more than 250 bone marrow samples, with a 93% success rate. Conclusions.-We believe the routine use of alteplase on clotted blood and bone marrow specimens should become standard for cytogenetics laboratories and may have similar utility in salvaging clotted specimens for other clinical assays requiring intact cells for analysis.

UR - http://www.scopus.com/inward/record.url?scp=79960806557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960806557&partnerID=8YFLogxK

M3 - Article

C2 - 21732783

AN - SCOPUS:79960806557

VL - 135

SP - 915

EP - 919

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 7

ER -